Hound Partners Has Raised Facebook (FB) Holding; Narwhal Capital Management Has Cut Its Cvs Health (CVS) Stake by $1.84 Million

April 22, 2018 - By Peter Erickson

CVS Health Corporation (NYSE:CVS) Logo

Jonathan Auerbach increased its stake in Facebook Inc (FB) by 82.47% based on its latest 2017Q4 regulatory filing with the SEC. Hound Partners Llc bought 552,622 shares as the company’s stock declined 14.10% with the market. The hedge fund run by Jonathan Auerbach held 1.22 million shares of the technology company at the end of 2017Q4, valued at $215.76M, up from 670,075 at the end of the previous reported quarter. Hound Partners Llc who had been investing in Facebook Inc for a number of months, seems to be bullish on the $482.11B market cap company. The stock decreased 1.08% or $1.82 during the last trading session, reaching $166.28. About 17.17M shares traded. Facebook, Inc. (NASDAQ:FB) has risen 8.48% since April 22, 2017 and is uptrending. It has underperformed by 3.07% the S&P500.

Narwhal Capital Management decreased its stake in Cvs Health Corp (CVS) by 83.64% based on its latest 2017Q4 regulatory filing with the SEC. Narwhal Capital Management sold 25,565 shares as the company’s stock declined 17.45% with the market. The hedge fund held 5,000 shares of the medical and nursing services company at the end of 2017Q4, valued at $363,000, down from 30,565 at the end of the previous reported quarter. Narwhal Capital Management who had been investing in Cvs Health Corp for a number of months, seems to be less bullish one the $66.20 billion market cap company. The stock decreased 0.37% or $0.24 during the last trading session, reaching $65.12. About 6.17M shares traded. CVS Health Corporation (NYSE:CVS) has declined 22.81% since April 22, 2017 and is downtrending. It has underperformed by 34.36% the S&P500.

Investors sentiment increased to 1.21 in 2017 Q4. Its up 0.06, from 1.15 in 2017Q3. It improved, as 57 investors sold FB shares while 621 reduced holdings. 147 funds opened positions while 670 raised stakes. 1.61 billion shares or 1.26% less from 1.63 billion shares in 2017Q3 were reported. Mcrae Inc holds 0.22% of its portfolio in Facebook, Inc. (NASDAQ:FB) for 2,904 shares. Eqis Capital Mgmt reported 0.18% of its portfolio in Facebook, Inc. (NASDAQ:FB). Lenox Wealth Advsr invested in 0.04% or 783 shares. Moreover, Tiaa Cref Invest Management Lc has 1.81% invested in Facebook, Inc. (NASDAQ:FB). Stoneridge Inv Prtn Ltd Limited Liability Company has 1.18% invested in Facebook, Inc. (NASDAQ:FB). Crestwood Advisors Group Incorporated Limited Liability accumulated 8,266 shares or 0.12% of the stock. 43,698 are held by Marketfield Asset Management Ltd Company. Sigma Planning reported 52,351 shares. Mufg Americas Corp holds 512,733 shares or 2.7% of its portfolio. Baker Ellis Asset Mgmt Llc holds 3,651 shares or 0.16% of its portfolio. Rbf Limited Liability Corp owns 86,700 shares. 4,348 were accumulated by Allsquare Wealth Mgmt Ltd Llc. 1.71M are owned by Gilder Gagnon Howe Limited Liability Com. Jackson Square Llc has invested 2.68% of its portfolio in Facebook, Inc. (NASDAQ:FB). Vanguard Gp Inc stated it has 1.31% in Facebook, Inc. (NASDAQ:FB).

Since October 23, 2017, it had 0 insider buys, and 41 insider sales for $1.41 billion activity. The insider Cox Christopher K sold 16,000 shares worth $2.80M. Sandberg Sheryl also sold $9.61M worth of Facebook, Inc. (NASDAQ:FB) shares. 38,017 shares were sold by Schroepfer Michael Todd, worth $7.14M on Tuesday, January 9. Stretch Colin sold $134,125 worth of stock. 4,699 Facebook, Inc. (NASDAQ:FB) shares with value of $806,019 were sold by FISCHER DAVID B.. $2.66 million worth of stock was sold by Wehner David M. on Thursday, February 22.

Among 55 analysts covering Facebook (NASDAQ:FB), 50 have Buy rating, 2 Sell and 3 Hold. Therefore 91% are positive. Facebook had 254 analyst reports since July 21, 2015 according to SRatingsIntel. Jefferies maintained Facebook, Inc. (NASDAQ:FB) rating on Thursday, November 5. Jefferies has “Buy” rating and $135.0 target. The stock of Facebook, Inc. (NASDAQ:FB) has “Buy” rating given on Thursday, November 3 by Jefferies. The firm has “Overweight” rating by Barclays Capital given on Thursday, November 5. RBC Capital Markets maintained it with “Outperform” rating and $170 target in Thursday, November 3 report. The stock has “Buy” rating by Canaccord Genuity on Thursday, November 3. The firm earned “Hold” rating on Thursday, March 22 by Stifel Nicolaus. The stock has “Outperform” rating by Wells Fargo on Thursday, November 3. Credit Suisse maintained the shares of FB in report on Friday, October 9 with “Outperform” rating. The stock has “Overweight” rating by Barclays Capital on Thursday, November 2. The stock of Facebook, Inc. (NASDAQ:FB) earned “Positive” rating by Susquehanna on Thursday, April 28.

Hound Partners Llc, which manages about $3.00B and $3.64B US Long portfolio, decreased its stake in Equifax Inc (NYSE:EFX) by 234,111 shares to 921,094 shares, valued at $108.62M in 2017Q4, according to the filing. It also reduced its holding in Lkq Corp (NASDAQ:LKQ) by 236,071 shares in the quarter, leaving it with 9.58 million shares, and cut its stake in Mohawk Inds Inc (NYSE:MHK).

Narwhal Capital Management, which manages about $490.63M and $435.07 million US Long portfolio, upped its stake in Molson Coors Brewing Co (NYSE:TAP) by 18,370 shares to 29,815 shares, valued at $2.45M in 2017Q4, according to the filing. It also increased its holding in American Intl Group Inc (NYSE:AIG) by 14,231 shares in the quarter, for a total of 96,323 shares, and has risen its stake in Unitedhealth Group Inc (NYSE:UNH).

Investors sentiment decreased to 0.72 in 2017 Q4. Its down 0.16, from 0.88 in 2017Q3. It fall, as 115 investors sold CVS shares while 600 reduced holdings. 134 funds opened positions while 380 raised stakes. 815.59 million shares or 1.76% more from 801.45 million shares in 2017Q3 were reported. Carnegie Asset Limited Liability Corporation reported 0.27% of its portfolio in CVS Health Corporation (NYSE:CVS). Hudson Valley Advisors Adv holds 0.6% or 33,293 shares. Bailard Incorporated has 52,217 shares for 0.24% of their portfolio. Wolverine Asset Mngmt Lc has 6,584 shares. Ally Inc reported 90,000 shares. Cadence Bancorp Na has 12,697 shares for 0.34% of their portfolio. 34,919 were accumulated by Landscape Management Limited Liability Com. Leavell Management stated it has 0.05% of its portfolio in CVS Health Corporation (NYSE:CVS). Calamos Ltd Llc accumulated 0.05% or 144,771 shares. James Inv Incorporated invested in 0.02% or 7,904 shares. The Georgia-based Signaturefd Limited Liability Corp has invested 0.08% in CVS Health Corporation (NYSE:CVS). Marco Investment Management Ltd Liability Company invested 0.49% in CVS Health Corporation (NYSE:CVS). Advent Management De has 18,600 shares. 1.81 million are held by Citigroup Inc. 73 were accumulated by Guinness Asset Mngmt Limited.

Among 26 analysts covering CVS Health (NYSE:CVS), 19 have Buy rating, 0 Sell and 7 Hold. Therefore 73% are positive. CVS Health had 76 analyst reports since July 22, 2015 according to SRatingsIntel. On Monday, June 20 the stock rating was downgraded by Morgan Stanley to “Equal-Weight”. On Thursday, March 10 the stock rating was reinitiated by Barclays Capital with “Overweight”. The stock has “Hold” rating by Loop Capital on Tuesday, November 7. The rating was initiated by UBS on Thursday, October 6 with “Buy”. The rating was maintained by Oppenheimer with “Outperform” on Friday, August 28. The rating was maintained by Robert W. Baird on Friday, October 27 with “Hold”. Robert W. Baird downgraded the stock to “Neutral” rating in Thursday, February 2 report. The firm has “Neutral” rating given on Friday, November 3 by Citigroup. As per Wednesday, January 17, the company rating was maintained by Robert W. Baird. The company was maintained on Monday, January 8 by Leerink Swann.

Since February 16, 2018, it had 0 insider purchases, and 1 insider sale for $1.42 million activity.

CVS Health Corporation (NYSE:CVS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: